Skip to main content
. 2023 May 26;16(6):791. doi: 10.3390/ph16060791

Figure 10.

Figure 10

Adverse effects induced by latanoprostene bunod (LBN; 0.024%, once daily), latanoprost (0.005%, once daily), or timolol (0.05%, twice daily) following topical ocular administration in OAG/OHT patients (Figure 9) covering treatments from 1 week to 12 months are shown.